Tammuella Chrisentery-Singleton/LinkedIn
Aug 8, 2026, 20:37
Tammuella Chrisentery-Singleton: What Comes Next for Hemophilia Care With Non-Factor Therapies?
Tammuella Chrisentery-Singleton, Chief Science Officer at American Thrombosis and Hemostasis Network (ATHN), Co- Director Hemostasis and Thrombosis Program at Ochsner Health, shared a post on LinkedIn:
“After the long trip home from ISTH, I’m excited to bring new insights back to the clinic as we think about what comes next for
hemophilia care with non-factor therapies now being available across the world.
Note: This content is intended for healthcare professionals only.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Aug 8, 2026, 20:36Michelle Cha: The Evolving Role of Nurse Coordinators in Hemophilia Gene Therapy
-
Aug 8, 2026, 20:35Benjamin Schumacher: The Future of Holistic Haemophilia A Care
-
Aug 8, 2026, 20:33Delilah F.: March Is Blood Clot Awareness Month
-
Aug 8, 2026, 20:31Jackie Maybin: Top 10 Research Priorities for Problematic Menstrual Bleeding in the UK
-
Aug 8, 2026, 17:02Mohammed Murad Hossain: Highlights from the 2nd Haematology and HSCT Workshop in Dhaka
-
Aug 8, 2026, 16:57Mohammed Al Kanan: Advancing Therapeutic Drug Monitoring in Pediatric Aplastic Anemia
-
Aug 8, 2026, 16:38Dmytro Samofalov: FDA-Approved Freeze-Dried Plasma in Modern Warfare
-
Aug 8, 2026, 16:33Roshan Koshy Jacob: When Unexplained Severe Anemia Points to Myelodysplastic Neoplasms
-
Aug 8, 2026, 16:21Sheharyar Raza: Transfusion Medicine in the Age of AI Slop